45 CFR § 180 compliance
A · 100
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
6,578
Insurances with rates
6
CPT / HCPCS codes
6,062
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J2326 | Nusinersen (PF) 12 mg/5 mL Soln 5 mL VIAL | $351,752 | $123,113 | $824 | $1,908 | 3 |
| Q9982 | Flutemetamol F-18 5 mCi (185 MBq) Soln 1 Each VIAL | $228,141 | $79,849 | $44,259 | $102,663 | 3 |
| Q2043 | Sipuleucel-T in LR 50 million cell/250 mL Susp 250 mL BAG | $180,340 | $63,119 | $40,461 | $93,695 | 3 |
| J0224 | Lumasiran 94.5 mg/0.5 mL Soln 0.5 mL VIAL | $163,157 | $57,105 | $224 | $519 | 3 |
| A9513 | Lutetium Lu 177 Dotatate 10 mCi/mL (370 mBq/mL) Soln 1 Each VIAL | $153,434 | $53,702 | $29,766 | $69,045 | 3 |
| 90288 | Botulism Immune Globulin (Human) 100 mg Recon soln 1 Each VIAL | $137,525 | $48,134 | $26,680 | $61,886 | 3 |
| J7352 | Afamelanotide 16 mg Implant 1 Each VIAL | $135,363 | $47,377 | $2,363 | $5,472 | 3 |
| J9226 | Histrelin 50 mg (65 mcg/day) Kit 1 Each KIT | $130,121 | $45,542 | $31,055 | $71,914 | 3 |
| J1823 | Inebilizumab-cdon 10 mg/mL Soln 10 mL VIAL | $125,765 | $44,018 | $340 | $787 | 3 |
| A9607 | Lutetium Lu-177 Vipivotide tetraxetan 27 mCi/mL (1,000 MBq/mL) Soln 1 Each VIAL | $122,445 | $42,856 | $23,754 | $55,100 | 3 |
| J0223 | Givosiran 189 mg/mL Soln 1 mL VIAL | $115,695 | $40,493 | $79 | $184 | 3 |
| C9293 | Glucarpidase 1,000 unit Recon soln 1 Each VIAL | $105,551 | $36,943 | $20,477 | $47,498 | 3 |
| 64582 | OPEN IMPLTJ HPGLSL NRV NSTIM RA PG&RESPIR SENSOR | $100,767 | $35,268 | $29,636 | $80,098 | 3 |
| J9228 | Ipilimumab 200 mg/40 mL (5 mg/mL) Soln 40 mL VIAL | $92,670 | $32,434 | $120 | $278 | 3 |
| J9269 | Tagraxofusp-erzs 1,000 mcg/mL Soln 1 mL VIAL | $89,074 | $31,176 | $227 | $526 | 3 |
| A9543 | YTTRIUM Y-90 IBRITUMOMAB TIUXETAN TX TO 40 MCI | $84,557 | $29,595 | $15,643 | $42,279 | 3 |
| J0202 | Alemtuzumab 12 mg/1.2 mL Soln 1.2 mL VIAL | $77,973 | $27,290 | $1,611 | $3,731 | 3 |
| 33270 | INS/RPLCMNT PERM SUBQ IMPLTBL DFB W/SUBQ ELTRD | $77,795 | $27,228 | $33,070 | $89,379 | 3 |
| J2507 | Pegloticase 8 mg/mL Soln 1 mL VIAL | $76,801 | $26,880 | $2,284 | $5,288 | 3 |
| J9118 | Calaspargase pegol-mknl 750 unit/mL Soln 5 mL VIAL | $72,140 | $25,249 | $13,995 | $32,463 | 3 |
| 33289 | TCAT IMPL WRLS P-ART PRS SNR L-T HEMODYN MNTR | $69,595 | $24,358 | $23,175 | $62,636 | 3 |
| J9359 | Loncastuximab Tesirine-lpyl 10 mg Recon soln 1 Each VIAL | $69,530 | $24,336 | $138 | $320 | 3 |
| J0593 | Lanadelumab-flyo 300 mg/2 mL (150 mg/mL) Soln 2 mL VIAL | $69,460 | $24,311 | $13,475 | $31,257 | 3 |
| 33231 | INSJ IMPLNTBL DEFIB PULSE GEN W/EXIST MULTILEADS | $67,256 | $23,540 | $33,070 | $89,379 | 3 |
| 33262 | RMVL IMPLTBL DFB PLSE GEN W/REPL PLSE GEN 1 LEAD | $65,383 | $22,884 | $23,216 | $62,747 | 3 |
| J9281 | mitoMYcin 40 mg x 2 Kit 1 Each VIAL | $65,266 | $22,843 | $209 | $485 | 3 |
| J1951 | Leuprolide (Pediatric 6 Month) 45 mg Syringe 1 Each SYRINGE | $65,030 | $22,760 | $98 | $227 | 3 |
| J9348 | Naxitamab-gqgk 4 mg/mL Soln 10 mL VIAL | $63,229 | $22,130 | $409 | $948 | 3 |
| 33263 | RMVL IMPLTBL DFB PLSE GEN W/RPLCMT PLSE GEN 2 LD | $63,139 | $22,099 | $23,216 | $62,747 | 3 |
| J9600 | Porfimer 75 mg Recon soln 1 Each VIAL | $62,357 | $21,825 | $16,045 | $37,156 | 3 |
| 33264 | RMVL IMPLTBL DFB PLS GEN W/RPLCMT PLS GEN MLT LD | $61,522 | $21,533 | $33,070 | $89,379 | 3 |
| 33230 | INSJ IMPLNTBL DEFIB PULSE GEN W/EXIST DUAL LEADS | $61,174 | $21,411 | $23,216 | $62,747 | 3 |
| J9229 | Inotuzumab Ozogamicin 0.9 mg (0.25 mg/mL initial) Recon soln 1 Each VIAL | $60,687 | $21,240 | $1,794 | $4,154 | 3 |
| C9758 | BI PROC NYHA CL III/IV HF;TRNSCATH IMPL IAS/PC | $59,515 | $20,830 | $11,010 | $29,758 | 3 |
| 33240 | INSJ IMPLNTBL DEFIB PULSE GEN W/1 EXISTING LD | $55,933 | $19,577 | $23,216 | $62,747 | 3 |
| 37227 | REVSC OPN/PRQ FEM/POP W/STNT/ATHRC/ANGIOP SM VSL | $55,237 | $19,333 | $16,169 | $43,700 | 3 |
| J7311 | Fluocinolone 0.59 mg Implant 1 Each PACKET | $54,797 | $19,179 | $244 | $565 | 3 |
| 0620T | ENDOVASCULAR VENOUS ARTERIALIZATION TIBL/PRNL VN | $54,505 | $19,077 | $10,083 | $27,253 | 3 |
| C9774 | REVASC LITHOTR-ATHER TIB/PER | $54,505 | $19,077 | $10,083 | $27,253 | 3 |
| C9773 | REVASC LITHOTR-STENT TIB/PER | $54,505 | $19,077 | $10,083 | $27,253 | 3 |
| C9775 | REVASC LITH-STEN-ATH TIB/PER | $54,505 | $19,077 | $10,083 | $27,253 | 3 |
| J9274 | Tebentafusp-tebn 100 mcg/0.5 mL Soln 0.5 mL VIAL | $54,074 | $18,926 | $10,490 | $24,333 | 3 |
| J9266 | PEGaspargase 750 unit/mL Soln 5 mL VIAL | $53,617 | $18,766 | $17,292 | $40,043 | 3 |
| J3316 | Triptorelin 22.5 mg Recon susp 1 Each VIAL | $52,435 | $18,352 | $2,249 | $5,207 | 3 |
| 36837 | PERQ AV FISTULA CREATION UXTR SEP ACCESS SITES | $51,533 | $18,037 | $17,160 | $46,380 | 3 |
| 36836 | PERQ AV FISTULA CREATION UXTR SINGLE ACCESS | $51,533 | $18,037 | $17,160 | $46,380 | 3 |
| 33902 | PERQ P-ART REVSC ST 1ST ABNOR CONNJ UNILATERAL | $51,533 | $18,037 | $17,160 | $46,380 | 3 |
| J2350 | Ocrelizumab 30 mg/mL Soln 10 mL VIAL | $51,260 | $17,941 | $44 | $103 | 3 |
| J0638 | Canakinumab (PF) 150 mg/mL Soln 1 mL VIAL | $49,321 | $17,262 | $87 | $202 | 3 |
| 37231 | REVSC OPN/PRQ TIB/PERO W/STNT/ATHR/ANGIOP SM VSL | $49,145 | $17,201 | $16,169 | $43,700 | 3 |
Showing top 50 of 6,578 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.